-
公开(公告)号：EP4139616A1
公开(公告)日：2023-03-01
申请号：EP21718593.3
申请日：2021-04-16
申请人： Pfizer Inc. , BioNTech SE
发明人： NAUTA, Marjoh , PEETERS, Dirk Jozef , VAN DOORSLAER, Tom Frank Steven , BADKAR, Advait Vijay , DARVARI, Ramin , WARNE, Nicholas William , JEAN, James , HENDRIKSE, Danny Pierre G. , SAHIN, Ugur , GÜLER, Alptekin , KUHN, Andreas , MUIK, Alexander , VOGEL, Annette , WALZER, Kerstin , WITZEL, Sonja , HEIN, Stephanie , TÜRECI, Özlem
IPC分类号： F25D3/12 , A61K39/215 , A61K45/06 , B65D81/18 , C12N15/00
-
公开(公告)号：EP4238577A2
公开(公告)日：2023-09-06
申请号：EP22203154.4
申请日：2022-10-21
申请人： BioNTech SE
摘要： This disclosure relates to technologies for preventing or treating coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses.
-
公开(公告)号：EP4238577A3
公开(公告)日：2023-12-06
申请号：EP22203154.4
申请日：2022-10-21
申请人： BioNTech SE
摘要： This disclosure relates to technologies for preventing or treating coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses.
-
公开(公告)号：EP2331090A1
公开(公告)日：2011-06-15
申请号：EP09787253.5
申请日：2009-09-18
申请人： Pfizer Inc.
IPC分类号： A61K31/198 , A61K47/18 , A61K47/26 , A61K9/00 , A61K39/395
CPC分类号： A61K9/0019 , A61K31/198 , A61K47/183 , A61K47/26
摘要： The present invention relates generally to the field of pharmaceutical formulations of antibodies. Specifically, the present invention relates to a stable liquid antibody formulation and its pharmaceutical preparation and use. This invention is exemplified by a liquid formulation of a humanised anti-NGF antibody.
摘要翻译： 本发明一般涉及抗体的药物制剂领域。 具体地说，本发明涉及稳定的液体抗体制剂及其药物制剂和用途。 本发明以人源化抗NGF抗体的液体制剂为例。
-
公开(公告)号：EP4333880A1
公开(公告)日：2024-03-13
申请号：EP22722898.8
申请日：2022-04-29
申请人： Pfizer Inc.
-
公开(公告)号：EP2331090B1
公开(公告)日：2018-01-03
申请号：EP09787253.5
申请日：2009-09-18
申请人： Pfizer Inc.
IPC分类号： A61K31/198 , A61K47/18 , A61K47/26 , A61K9/00 , A61K39/395
CPC分类号： A61K9/0019 , A61K31/198 , A61K47/183 , A61K47/26
摘要： The present invention relates generally to the field of pharmaceutical formulations of antibodies. Specifically, the present invention relates to a stable liquid antibody formulation and its pharmaceutical preparation and use. This invention is exemplified by a liquid formulation of a humanised anti-NGF antibody.
-
公开(公告)号：EP4412646A1
公开(公告)日：2024-08-14
申请号：EP22792916.3
申请日：2022-10-05
申请人： Pfizer Inc.
-
公开(公告)号：EP3329911A1
公开(公告)日：2018-06-06
申请号：EP17209015.1
申请日：2009-09-18
申请人： Pfizer Inc.
IPC分类号： A61K31/198 , A61K47/18 , A61K47/26 , A61K9/00 , A61K39/395
CPC分类号： A61K9/0019 , A61K31/198 , A61K47/183 , A61K47/26
摘要： The present invention relates generally to the field of pharmaceutical formulations of antibodies. Specifically, the present invention relates to a stable liquid antibody formulation and its pharmaceutical preparation and use. This invention is exemplified by a liquid formulation of a humanised anti-NGF antibody.
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.013 秒)
